Soley Therapeutics Announces $200 Million Series C Financing to Propel Lead Oncology Programs into the Clinic and Scale Its Cell Stress Sensing Platform

On January 7, 2026 Soley Therapeutics ("Soley") reported a $200 million Series C financing to advance its proprietary cell stress sensing platform and pipeline of novel therapeutics into the clinic. Proceeds will support IND-enabling work and clinical trials for two first-in-class internally discovered and developed oncology assets, in addition to advancement of the non-oncology stress-reducing drug candidates for neurodegenerative disorders and metabolic diseases, and continued platform scale-up.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New investors in this round included Surveyor Capital as primary investor, joined by HRTG Partners, RWN Management, and others. Existing Soley investors, including Doug Leone Family Fund, Breyer Capital, and GordonMD Global Investments LP, and other undisclosed investors also participated.

The Soley platform captures time-resolved responses across thousands of features in human cells, then uses proprietary computer vision and AI to convert those features into compact, structured signatures. It screens hundreds of thousands of compounds per week, generates reproducible data at scale in-house using first-in-class automation and robotics, and trains proprietary AI/ML models, to accelerate hit finding, mechanistic insights, and molecule design.

"We built Soley to measure how living human cells, in health and disease, respond to drug exposure and determine their fate. We then translate this cellular information into a robust portfolio of novel drug candidates across a broad range of disease areas and indications," said Yerem Yeghiazarians, M.D., Co-founder and CEO of Soley Therapeutics. "We are thrilled by the strong investor support from life sciences and technology focused funds as we advance our lead programs into the clinic and expand our platform to continue building a first-in-class pipeline."

(Press release, Soley Therapeutics, JAN 7, 2026, View Source [SID1234661813])